S. Samimi

A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine

S. Kalloger, C. Chow, J. Mackey, 2017, The journal of pathology. Clinical research.

Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system

J. Kwon, B. Gilks, Sophie Sun, 2020, Cancer medicine.

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer

D. Tu, H. Kennecke, P. Kavan, 2020, JAMA oncology.

Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada.

L. Dawson, E. Dixon, D. Valenti, 2023, Cancer treatment reviews.

CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).

D. Tu, H. Kennecke, P. Kavan, 2019, Journal of Clinical Oncology.

Top 10 research priorities for early-stage colorectal cancer: a Canadian patient-oriented priority-setting partnership

C. Cuthbert, W. Cheung, R. Ramjeesingh, 2022, CMAJ open.

Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer

E. Titmuss, J. Goffin, J. Loree, 2023, JAMA network open.

Real-World Safety and Effectiveness of a Bevacizumab Biosimilar (ABP 215) in Metastatic Colorectal Cancer Patients in Canada.

S. Kassam, M. Trinkaus, Mistre Alemayehu, 2023, Clinical colorectal cancer.